P11.17 Splicing dysregulation drives glioblastoma malignancy: SRSF3 as a potential therapeutic target to impair glioblastoma progression

Glioblastomas (GBMs) remain the deadliest human brain tumors, with poor prognosis despite years of research. Currently, standard therapeutic strategies to treat GBM are not efficient and common survival from diagnosis is ~12–16 months. Thus, identification of new diagnostic/prognostic/therapeutic to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Fuentes-Fayos, A C, Vázquez-Borrego, M C, Jiménez-Vacas, J M, Bejarano, L, Blanco-Acevedo, C, Sánchez-Sánchez, R, Solivera, J, Blasco, M A, Castaño, J P, Luque, R M
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Poster Presentations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6796159/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz126.163
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados